Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies

Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies

US Patent 12419954 · Granted Sep 23, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Humanized anti-tissue factor antibody, antibody-drug conjugate prepared therefro2025
CD6 targeted chimeric antigen receptors for treatment of certain autoimmune diso2025
Affibody proteins specific for B7-H3 (CD276)2025
Evaluating performance of X-ray tube2025
Method of producing Th9 T-cells2025
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy2024
Sulfite-free, rapid setting, thermal-reversible modified potato starch gelling a2024
T cells for expression of chimeric antigen receptors and other receptors2024
Therapeutic IL-13 polypeptides2024
Foodstuffs comprising treated fava bean protein concentrates2024
CD123-specific chimeric antigen receptor redirected t cells and methods of their2024
Antibody for binding to interleukin 4 receptor2024